Molbio Diagnostics IPO: A High-Risk Bet with Potential Long-Term Gains
Molbio Diagnostics plans to raise ₹200 crore for expansion and reduce promoter stake with an IPO. High-risk investors may find long-term growth potential.
Molbio Diagnostics is set to launch an initial public offering (IPO) aimed at raising ₹200 crore for capital expenditures and reducing its promoter stake. The molecular diagnostics firm, which has been operational since 2000, plans to generate an additional ₹740 crore through an offer for sale, which will reduce the promoter group's stake from 46.6% to 43% post-IPO.
Expanding Global Footprint
With six manufacturing facilities spread across India, Molbio Diagnostics serves clients in over 90 countries. Its key customers, including government health programs and international healthcare organizations, contribute a significant portion of its revenue. The company's flagship product, the 'Truenat' platform, is a portable diagnostics system providing rapid test results, particularly useful in resource-limited settings.
Financial Performance and Revenue Sources
Molbio Diagnostics has demonstrated substantial financial growth over recent years. Between fiscal years 2024 and 2026, the company's revenue from operations surged by 31.5% annually to ₹1,445.7 crore. During the same period, net profit increased by 40.2% annually to ₹164.1 crore. The operating profit before interest, tax, depreciation, and amortization (EBITDA) also saw a 33.2% rise, reaching ₹328.2 crore. The EBITDA margin improved to 22.6% in FY26 from 22% in FY24.
The company's primary revenue driver is its range of diagnostic test kits, which account for nearly 74% of total sales. Of this, 70% is derived from tuberculosis diagnostic kits, underscoring the importance of this product line to Molbio's business model.
Market Valuation and Investor Considerations
Molbio Diagnostics is seeking a price-to-earnings (P/E) multiple of up to 57, based on its post-IPO equity and FY26 net profit projections. While the company lacks directly comparable listed peers in India, other firms in the healthcare diagnostics and medical device sectors, such as Poly Medicure and Dr. Lal PathLabs, trade at P/E multiples ranging from 54 to 81.
For investors with a high-risk tolerance, Molbio's IPO presents an opportunity for potential long-term growth. The company's strong revenue growth, global reach, and focus on innovative diagnostic solutions position it as a compelling option in the diagnostics industry.